drugset / Trial / NCT05423197
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2026-06
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-panitumumab | Diagnostic / imaging agent | 1 mbq | Intravenous |
| Comparator | Panitumumab | Monoclonal antibody | 30 mg | Oral |